CalciMedica, Inc. Common Stock (CALC) - Total Liabilities
Based on the latest financial reports, CalciMedica, Inc. Common Stock (CALC) has total liabilities worth $20.23 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CalciMedica, Inc. Common Stock - Total Liabilities Trend (2018–2025)
This chart illustrates how CalciMedica, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See CalciMedica, Inc. Common Stock current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
CalciMedica, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of CalciMedica, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MILA RESOUR. PLC LS-01
F:HN0
|
Germany | €116.74K |
|
Manho Rope&Wir
KO:001080
|
Korea | ₩22.54 Billion |
|
Medadvisor Ltd
AU:MDR
|
Australia | AU$41.46 Million |
|
Filtronic
LSE:FTC
|
UK | GBX14.42 Million |
|
Meta Epsi Tbk PT
JK:MTPS
|
Indonesia | Rp31.10 Billion |
|
Citatah Tbk
JK:CTTH
|
Indonesia | Rp493.94 Billion |
|
Spineguard
PA:ALSGD
|
France | €4.07 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down CalciMedica, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of CalciMedica, Inc. Common Stock.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CalciMedica, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CalciMedica, Inc. Common Stock (2018–2025)
The table below shows the annual total liabilities of CalciMedica, Inc. Common Stock from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $20.23 Million | +275.78% |
| 2024-12-31 | $5.38 Million | +33.66% |
| 2023-12-31 | $4.03 Million | -67.99% |
| 2022-12-31 | $12.58 Million | +209.52% |
| 2021-12-31 | $4.07 Million | -41.99% |
| 2020-12-31 | $7.01 Million | -42.80% |
| 2019-12-31 | $12.25 Million | +111.44% |
| 2018-12-31 | $5.79 Million | -- |
About CalciMedica, Inc. Common Stock
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxi… Read more